Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410981 · ClinicalTrials.gov registry record
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 73
- Enrollment target
NCT01410981 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 73 participants.
The verdict
NCT01410981 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that had been done before the subject entered this study will be provided for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47, sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim kinase inhibitors provide a new agent for the treatment of multiple myeloma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410981
The ClinicalTrials.gov registry entry for NCT01410981 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01410981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410981 about?
NCT01410981 is a clinical study titled "Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma". The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cell...
What is the current status of trial NCT01410981?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2011-08. Estimated completion is 2014-06.
Who is sponsoring clinical trial NCT01410981?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.